Phaseline

Companies › Prospect Therapeutics (Nanjing)

Prospect Therapeutics (Nanjing): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Other; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PSTB100–Phase 1Healthy Adult SubjectsJun 2027
PSTC100 tablets–Phase 1Healthy Adult SubjectsJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07702279PSTB100Phase 1Healthy Adult SubjectsOtherJun 2027
NCT07752472PSTC100 tabletsPhase 1Healthy Adult SubjectsOtherJul 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.